Novavax has got $97m for first three years with an option to extend for additional two years for a total contract value of $179.1m.
However, HHS has awarded $117.9m to VaxInnate for the first three years, which can be extended for two additional years, for a total contract value of $196.6m.
Under the contract, Novavax is expected to develop new technology for the production of vaccines while using insect cells to express influenza proteins and create virus-like particles that stimulate a strong immune response in humans.
Novavax and VaxInnate are expected to conduct clinical safety and efficacy studies as well as optimize and validate their manufacturing processes.